Tumor Biology

, Volume 35, Issue 2, pp 1177–1182 | Cite as

G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis

  • Hang Huang
  • Bing Cai
Research Article


The rare but recurrent germline G84E mutation in HOXB13 was recently found to be associated with a significantly increased risk of familial prostate cancer (PCa). However, epidemiologic findings have been inconsistent. In an attempt to confirm and expand the findings that the PCa risk increased in men carrying G84E, we therefore performed a meta-analysis to clarify the association between the germline G84E mutation and PCa risk. We also aim to verify the increased PCa risk with respect to diagnostic age, family history, and disease aggressiveness. Comprehensive search of databases was carried out, and other relevant articles were also identified. Then, the meta-analyses were conducted according to the standard guidelines. A total of 11 studies with 120,167 participants were included on the basis of inclusion criteria. The G84E allele carrier frequencies ranged from 0.1 to 4.9 % in the patients with PCa, as compared with 0 to 1.4 % in control subjects. Men with the HOXB13 G84E variant had a 4.51-fold higher relative risk of PCa compared with non-carriers (95 % CI 3.28–6.20). The much higher risks were observed in individuals with early onset (odds ratio (OR) = 9.73, 95 % confidence interval (CI) 6.57–14.39), more than two affected relatives (OR = 7.27, 95 % CI 4.02–13.15), and highly aggressive disease (OR = 5.81, 95 % CI 3.72–9.08). Our findings provide further evidences that the rare mutation in HOXB13 contributes to both hereditary and sporadic PCa risk. Despite the low G84E carrier rate, biological and clinical implications of the mutation in subjects with early onset, more than two affected relatives, and highly aggressive disease remain important in continued investigation.


HOXB13 G84E Mutation Prostatic neoplasms Meta-analysis 


Conflicts of interest


Supplementary material

13277_2013_1157_MOESM1_ESM.pdf (215 kb)
ESM 1 (PDF 214 kb)


  1. 1.
    Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, et al. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation. Prostate. 2010;70:1729–38.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011;43:785–91.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366:141–9.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol. 2012. doi: 10.1016/j.eururo.2012.07.027.PubMedGoogle Scholar
  5. 5.
    Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet. 2013;132:5–14.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.PubMedCrossRefGoogle Scholar
  8. 8.
    Handoll HH. Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil. 2006;87:875.PubMedCrossRefGoogle Scholar
  9. 9.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhu S, Zhang H, Xie L, Chen J, Niu Y. Risk factors and prevention of inguinal hernia after radical prostatectomy: a systematic review and meta-analysis. J Urol. 2013;189:884–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Stott-Miller M, Karyadi DM, Smith T, Kwon EM, Kolb S, Stanford JL, et al. HOXB13 mutations in a population-based, case–control study of prostate cancer. Prostate. 2012. doi: 10.1002/pros.22604.PubMedGoogle Scholar
  12. 12.
    Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith JR. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:1348–53.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Gudmundsson J, Sulem P, Gudbjartsson DF, Masson G, Agnarsson BA, Benediktsdottir KR, et al. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet. 2012;44:1326–9.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Akbari MR, Trachtenberg J, Lee J, Tam S, Bristow R, Loblaw A, et al. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst. 2012;104:1260–2.PubMedCrossRefGoogle Scholar
  15. 15.
    Kluzniak W, Wokolorczyk D, Kashyap A, Jakubowska A, Gronwald J, Huzarski T, et al. The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate. 2013;73:542–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Chen Z, Greenwood C, Isaacs WB, Foulkes WD, Sun J, Zheng SL, et al. The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. Carcinogenesis. 2013;34:1260–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Witte JS, Mefford J, Plummer SJ, Liu J, Cheng I, Klein EA, et al. HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease. Cancer Epidemiol Biomarkers Prev. 2013;22:675–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, et al. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2013;22:452–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, et al. A novel Germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate. 2013;73:169–75.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Economides KD, Capecchi MR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development. 2003;130:2061–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Kondo T, Zakany J, Innis JW, Duboule D. Of fingers, toes and penises. Nature. 1997;390:29.PubMedCrossRefGoogle Scholar
  22. 22.
    Podlasek CA, Duboule D, Bushman W. Male accessory sex organ morphogenesis is altered by loss of function of Hoxd-13. Dev Dyn. 1997;208:454–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Warot X, Fromental-Ramain C, Fraulob V, Chambon P, Dolle P. Gene dosage-dependent effects of the Hoxa-13 and Hoxd-13 mutations on morphogenesis of the terminal parts of the digestive and urogenital tracts. Development. 1997;124:4781–91.PubMedGoogle Scholar
  24. 24.
    Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21:224–34.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Chen J, Zhu S, Jiang N, Shang Z, Quan C, Niu Y. HoxB3 promotes prostate cancer cell progression by transactivating CDCA3. Cancer Lett. 2012;330:217–24.PubMedCrossRefGoogle Scholar
  26. 26.
    Klein C, Lohmann K, Ziegler A. The promise and limitations of genome-wide association studies. JAMA. 2012;8:1–2.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of UrologyThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina

Personalised recommendations